Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Insights
  5. Vantage Data Points
  6. Share Price Catalysts June 2019
Vantage Logo
July 03, 2019

Share price catalysts: June 2019

  • author
  • Edwin Elmhirst
  • Evaluate purple arrow

share price catalysts June 2019
Vantage Data Points

Related Companies

Acer Therapeutics
Aclaris Therapeutics
Adaptive Biotechnologies
InflaRx
La Jolla Pharmaceutical
Melinta Therapeutics
NovaBay Pharmaceuticals
Provention Bio
Savara Pharmaceuticals
VBI Vaccines
Download PDF

Share This Article

 

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Related Articles

Vantage logo
December 22, 2022

Go or no go? Lecanemab’s destiny approaches

Vantage logo
June 22, 2020

Tetraphase’s love quadrangle sees three bald men fight over a comb

Vantage logo
November 04, 2019

Share price movers – October 2019

Vantage logo
October 04, 2019

Japanese drugmakers stand out at the nine-month mark

Vantage logo
May 02, 2023

US FDA approval and panel tracker: April 2023

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up